MGNX Stock Analysis: Buy, Sell, or Hold?
MGNX - MacroGenics, Inc.
$4.71
0.09 (1.95%)
▲
5d:
+1.07%
30d:
+16.3%
90d:
+62.41%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When MGNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MGNX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MGNX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MGNX is currently trading at $4.71, which is considered extended relative to its 30-day fair value range of $3.94 to $4.57.
Technical Outlook: Technically, MGNX is in a strong uptrend. The price is approaching resistance at $4.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MGNX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.75 (+43.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MGNX is in a strong uptrend. The price is approaching resistance at $4.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MGNX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.75 (+43.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.94 -
$4.57
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.3% below Wall St target ($6.75)
Trading Range Analysis
30-Day Trading Range
$3.94 -
$4.57
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.84
Resistance Level
$4.64
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.33
Wall Street Target
$6.75
(+43.3%)
Revenue Growth (YoY)
57.5%
Earnings Growth (YoY)
-70.4%
Profit Margin
-44.8%
Share & Embed Analysis
Last updated: July 02, 2026 10:48 PM ET
Data refreshes hourly during market hours. Next update: 11:48 PM
Data refreshes hourly during market hours. Next update: 11:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MGNX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |
